FDA approves Johnson & Johnson’s nasal spray for depression as stand-alone treatment
Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...
Johnson & Johnson says positioned for 5%-7% growth through 2030 and beyond
Says starting 2025 from a position of strength. Says invested ~$50B in R&D and M&A in 2024. Says continues to invest in R&D at ...
Ben Johnson lays down his course for immediate Bears success
The idea of slowly building up a foundation is not part of Ben Johnson's plan for the Bears as he sees the chance for ...
MassDevice11h
Johnson & Johnson MedTech sales grow 6.2% in 2025, driven by EP, Abiomed
Johnson & Johnson (NYSE: JNJ) shares dipped slightly before hours today on fourth-quarter results that topped the consensus ...
New Bears coach Ben Johnson excited to take charge of ‘sleeping giant’
Johnson acknowledged that QB Caleb Williams was a key factor in him taking the job and "this offense will be calibrated with ...
Ben Johnson to Chicago Bears is a gut punch because he knows the Detroit Lions' recipe
Chicago has hired Detroit Lions OC Ben Johnson to be their next head coach. The toughest division in the NFL could get even ...
Bronstein, Gewirtz & Grossman, LLC Encourages Johnson & Johnson (JNJ) Shareholders to Inquire about Securities Investigation
NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Johnson & Johnson clears a few hurdles, but Wall Street focuses on weak guidance
Johnson & Johnson’s stock dropped more than 3% Wednesday after the medical-technology and drug company beat estimates for the fourth quarter but as lower sales guidance for the year stoked fears of ...